Μe	ember Name: {{MEMFIRST}} {{MEMLAST}} DOB: {{MEMBERDOB}} PA Number: {{PANUMBER}}
{{P	ANUMCODE}}
	DISPLAY_PAGNAME}} PACDESCRIPTION}}
for {{(is fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated ms to {{COMPANY_NAME}} at {{CLIENT_PAG_FAX}}. Please contact {{COMPANY_NAME}} at CLIENT_PAG_PHONE}} with questions regarding the prior authorization process. When conditions are met, will authorize the coverage of {{DRUGNAME}}.
Par Ph Sp Ph Ph	tient's Name: {{MEMFIRST}} {{MEMLAST}} Date: {{TODAY}} tient's ID: {{MEMBERID}} Patient's Date of Birth: {{MEMBERDOB}} ysician's Name: {{PHYFIRST}} {{PHYLAST}} Patient Phone: << MEMPHONE>> ecialty: NPI#: ysician Office Telephone: {{PHYSICIANPHONE}} Physician Office Fax: {{PHYSICIANFAX}} ysician Office Address: << PHYADDRESS1>> << PHYADDRESS2>> << PHYCITY>>, << PHYSTATE>> PHYZIP>> ug Name: {{DRUGNAME}}
Ro	antity: Frequency: Strength: ute of Administration: Expected Length of Therapy:
	what is the diagnosis? Generalized myasthenia gravis (gMG) Other
2.	Is this a request for continuation of therapy with the requested medication? Yes No If No, skip to #5
3.	Is there evidence of unacceptable toxicity or disease progression while on the current regimen? ☐ Yes ☐ No
4.	Has the patient experienced a positive response to therapy (e.g., improvement in MG-ADL score, MG Manual Muscle Test (MMT), MG Composite)? <i>ACTION REQUIRED: If Yes, please attach chart notes or medical record documentation supporting positive response to therapy.</i> \square Yes \square No <i>No further questions.</i>
5.	Is the requested medication being used to treat a patient who is anti-acetylcholine receptor (AChR) antibody positive? ACTION REQUIRED: If Yes, please attach chart notes or medical record documentation of a positive anti-acetylcholine receptor (AChR) antibody test. \square Yes \square No
6.	What is the patient's Myasthenia Gravis Foundation of America (MGFA) clinical classification? **ACTION REQUIRED: Please attach chart notes or medical record documentation of MGFA clinical classification.** Class I Class II Class III Class IV Llass V Unknown
7.	What is the patient's score on the MG activities of daily living? <i>ACTION REQUIRED: Please attach chart notes or medical record documentation of MG-ADL score.</i> ☐ Less than 6 ☐ Greater than or equal to 6
8.	Has the patient had an inadequate response or intolerable adverse event to at least two immunosuppressive therapies over the course of at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate mycophenolate, tacrolimus)? ACTION REQUIRED: If Yes, please attach chart notes, medical records, or claims history documentation of previous medications tried, including response to therapy. Yes No
9.	Has the patient had an inadequate response or intolerable adverse event to at least one immunosuppressive therapy and intravenous immunoglobulin (IVIG) therapy over the course of at least 12 months? <i>ACTION REQUIRED: If Yes, please attach chart notes, medical records, or claims history documentation of previous medications tried, including response to therapy.</i> \square Yes \square No

Member Name: {{MEMFIRST}} {{MEMLAST}} DOB: {{MEMBERDOB}} PA Number: {{PANUMBER}}	.}
10. Does the patient have a documented clinical reason to avoid therapy with immunosuppressive agents and intravenous immunoglobulin (IVIG)? <i>ACTION REQUIRED: If Yes, please attach chart notes or medical record documentation of clinical reason to avoid therapy.</i> □ Yes □ No	l
I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.	
Prescriber (Or Authorized) Signature and Date	